Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 279.70
-0.80 (-0.29%)
At close: Mar 19, 2026
Zealand Pharma Revenue
In the year 2025, Zealand Pharma had annual revenue of 9.21B DKK with 14,598.86% growth. Zealand Pharma had revenue of 68.92M in the quarter ending December 31, 2025, with 660.99% growth.
Revenue
9.21B
Revenue Growth
+14,598.86%
P/S Ratio
2.14
Revenue / Employee
18.77M
Employees
501
Market Cap
19.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.21B | 9.15B | 14,598.86% |
| Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
| Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
| Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
| Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| ALK-Abelló | 6.31B |
| Bavarian Nordic | 6.24B |
Zealand Pharma News
- 7 days ago - Zealand Pharma A/S at Barclays Global Healthcare Conference Transcript - GuruFocus
- 10 days ago - Zealand Pharma to participate in upcoming investor conferences in March 2026 - GlobeNewsWire
- 13 days ago - Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling - Market Watch
- 13 days ago - Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Benzinga
- 13 days ago - Zealand Pharma slump wipes billions off its value after obesity drug data disappoints - Reuters
- 13 days ago - Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial - WSJ
- 14 days ago - Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity - GlobeNewsWire
- 4 weeks ago - Q4 2025 Zealand Pharma A/S Earnings Call Transcript - GuruFocus